Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lundbeck announces ‘encouraging results’ in clinical study

Lundbeck announces ‘encouraging results’ in clinical study

3rd October 2007

Lundbeck has announced “encouraging results” for its compound Lu AA21004 after a clinical study was carried out for its use in the treatment of Major Depressive Disorder.

The trial involved 426 patients with major depression and saw the compound give significant improvements on the primary efficacy endpoints while having an effective safety profile for both 5mg and 10mg.

Anders Gersel Pedersen, head of development at Lundbeck, declared his satisfaction over the results and went on to outline the potential promise of the compound.

“Lu AA21004 is the most advanced project within the new bis-aryl-sulphanyl amine class of compounds for the treatment of mood disorders and anxiety, and we look forward to further exploiting the potential of these novel projects,” he said.

Lundbeck and Takeda Pharmaceuticals are developing the compound and are currently working in partnership to plan the next step in Lu AA21004’s development.

The companies’ alliance, pledged last month, has seen Lundbeck and Takeda Pharmaceuticals work together in the development and commercialisation of several compounds in the US and Japan.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.